BACKGROUND: Braintype natriuretic peptide (BNP) or N-terminal segment of the prohormone (NT-proBNP) measured within the first few days after symptom onset offer prognostic information in patients with non- ST elevation acute coronary syndromes (ACS). METHODS AND RESULTS: This prospective cohort study included 493 patients with non-ST segment elevation ACS who underwent percutaneous coronary intervention in the Deutsches Herzzentrum and Klinikum rechts der Isar in Munich, Germany. NT-proBNP was measured on admission. Patients were divided into four groups according to quartiles of NT-proBNP. The primary end point of the study was mortality. Patients were followed for a median of 4.0 years [interquartile range 3.6 to 4.9 years]. During this time period, there were 65 deaths: 4 deaths in the 1st quartile, 9 deaths in the 2nd quartile, 16 deaths in the 3rd quartile and 36 deaths in the 4th quartile (Kaplan-Meier estimates of mortality: 3.4, 7.8, 16.0 and 33.9%; odds ratio [OR] 10.2, 95% confidence interval [CI] 4.5 to 23.5; P< 0.001 for 4th vs 1st quartile). Patients in the upper quartile of NT-proBNP had a more adverse cardiovascular risk profile than patients in lower quartiles of NT-proBNP. After adjustment in the Cox proportional hazards model, the NT-proBNP remained an independent correlate of mortality (adjusted hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.04 to 1.45, P = 0.014 for 4th vs 1st quartiles) but weaker than age (adjusted HR 2.11, 95% CI 1.53 to 2.90; P < 0.001 for a 10-year increase in age) or left ventricular ejection fraction (adjusted HR 1.35, 95% CI 1.09 to 1.68; P = 0.007 for a 10% decrease). CONCLUSION: N-terminal probrain natriuretic peptide is a marker of weak-to-moderate strength in predicting the long-term prognosis in patients with non-ST segment elevation acute coronary syndromes after percutaneous coronary intervention.
BACKGROUND: Braintype natriuretic peptide (BNP) or N-terminal segment of the prohormone (NT-proBNP) measured within the first few days after symptom onset offer prognostic information in patients with non- ST elevation acute coronary syndromes (ACS). METHODS AND RESULTS: This prospective cohort study included 493 patients with non-ST segment elevation ACS who underwent percutaneous coronary intervention in the Deutsches Herzzentrum and Klinikum rechts der Isar in Munich, Germany. NT-proBNP was measured on admission. Patients were divided into four groups according to quartiles of NT-proBNP. The primary end point of the study was mortality. Patients were followed for a median of 4.0 years [interquartile range 3.6 to 4.9 years]. During this time period, there were 65 deaths: 4 deaths in the 1st quartile, 9 deaths in the 2nd quartile, 16 deaths in the 3rd quartile and 36 deaths in the 4th quartile (Kaplan-Meier estimates of mortality: 3.4, 7.8, 16.0 and 33.9%; odds ratio [OR] 10.2, 95% confidence interval [CI] 4.5 to 23.5; P< 0.001 for 4th vs 1st quartile). Patients in the upper quartile of NT-proBNP had a more adverse cardiovascular risk profile than patients in lower quartiles of NT-proBNP. After adjustment in the Cox proportional hazards model, the NT-proBNP remained an independent correlate of mortality (adjusted hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.04 to 1.45, P = 0.014 for 4th vs 1st quartiles) but weaker than age (adjusted HR 2.11, 95% CI 1.53 to 2.90; P < 0.001 for a 10-year increase in age) or left ventricular ejection fraction (adjusted HR 1.35, 95% CI 1.09 to 1.68; P = 0.007 for a 10% decrease). CONCLUSION: N-terminal probrain natriuretic peptide is a marker of weak-to-moderate strength in predicting the long-term prognosis in patients with non-ST segment elevation acute coronary syndromes after percutaneous coronary intervention.
Authors: Torbjørn Omland; James A de Lemos; David A Morrow; Elliot M Antman; Christopher P Cannon; Christian Hall; Eugene Braunwald Journal: Am J Cardiol Date: 2002-02-15 Impact factor: 2.778
Authors: David A Morrow; James A de Lemos; Marc S Sabatine; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: S Talwar; I B Squire; P F Downie; A M Mccullough; M C Campton; J E Davies; D B Barnett; L L Ng Journal: Eur Heart J Date: 2000-09 Impact factor: 29.983
Authors: Christopher Heeschen; Christian W Hamm; Veselin Mitrovic; Nicte-Ha Lantelme; Harvey D White Journal: Circulation Date: 2004-11-08 Impact factor: 29.690
Authors: Tomas Jernberg; Bertil Lindahl; Agneta Siegbahn; Bertil Andren; Gunnar Frostfeldt; Bo Lagerqvist; Mats Stridsberg; Per Venge; Lars Wallentin Journal: J Am Coll Cardiol Date: 2003-12-03 Impact factor: 24.094
Authors: Konstantinos P Letsas; Gerasimos S Filippatos; Loukas K Pappas; Constantinos C Mihas; Virginia Markou; Ioannis P Alexanian; Michalis Efremidis; Antonios Sideris; Alan S Maisel; Fotios Kardaras Journal: Clin Res Cardiol Date: 2008-10-30 Impact factor: 5.460
Authors: Boris Bigalke; Konstantinos Stellos; Tobias Geisler; Stephan Lindemann; Andreas E May; Meinrad Gawaz Journal: Clin Res Cardiol Date: 2010-01-05 Impact factor: 5.460